banner add

UnitedHealth’s Revenues Rise, in First Earnings Report Since CEO’s Killing

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.

from NYT > Health https://ift.tt/f2jTkLn
via IFTTT

No comments

Immunotherapy Drug Spares Cancer Patients From Grisly Surgeries and Harsh Therapies

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an immunotherapy trial offe...

Theme images by PLAINVIEW. Powered by Blogger.